These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

235 related items for PubMed ID: 19123868

  • 1. The absence of CD4+ T cell count recovery despite receipt of virologically suppressive highly active antiretroviral therapy: clinical risk, immunological gaps, and therapeutic options.
    Gazzola L, Tincati C, Bellistrì GM, Monforte Ad, Marchetti G.
    Clin Infect Dis; 2009 Feb 01; 48(3):328-37. PubMed ID: 19123868
    [Abstract] [Full Text] [Related]

  • 2. Nadir CD4 T cell count as predictor and high CD4 T cell intrinsic apoptosis as final mechanism of poor CD4 T cell recovery in virologically suppressed HIV-infected patients: clinical implications.
    Negredo E, Massanella M, Puig J, Pérez-Alvarez N, Gallego-Escuredo JM, Villarroya J, Villarroya F, Moltó J, Santos JR, Clotet B, Blanco J.
    Clin Infect Dis; 2010 May 01; 50(9):1300-8. PubMed ID: 20367229
    [Abstract] [Full Text] [Related]

  • 3. Altered clonogenic capability and stromal cell function characterize bone marrow of HIV-infected subjects with low CD4+ T cell counts despite viral suppression during HAART.
    Isgrò A, Leti W, De Santis W, Marziali M, Esposito A, Fimiani C, Luzi G, Pinti M, Cossarizza A, Aiuti F, Mezzaroma I.
    Clin Infect Dis; 2008 Jun 15; 46(12):1902-10. PubMed ID: 18462177
    [Abstract] [Full Text] [Related]

  • 4. Low CD4+ T cell nadir is an independent predictor of lower HIV-specific immune responses in chronically HIV-1-infected subjects receiving highly active antiretroviral therapy.
    Siddique MA, Hartman KE, Dragileva E, Dondero M, Gebretsadik T, Shintani A, Peiperl L, Valentine F, Kalams SA.
    J Infect Dis; 2006 Sep 01; 194(5):661-5. PubMed ID: 16897665
    [Abstract] [Full Text] [Related]

  • 5. Naive T-cell depletion related to infection by X4 human immunodeficiency virus type 1 in poor immunological responders to highly active antiretroviral therapy.
    Delobel P, Nugeyre MT, Cazabat M, Sandres-Sauné K, Pasquier C, Cuzin L, Marchou B, Massip P, Cheynier R, Barré-Sinoussi F, Izopet J, Israël N.
    J Virol; 2006 Oct 01; 80(20):10229-36. PubMed ID: 17005700
    [Abstract] [Full Text] [Related]

  • 6. Microbial translocation is associated with sustained failure in CD4+ T-cell reconstitution in HIV-infected patients on long-term highly active antiretroviral therapy.
    Marchetti G, Bellistrì GM, Borghi E, Tincati C, Ferramosca S, La Francesca M, Morace G, Gori A, Monforte AD.
    AIDS; 2008 Oct 01; 22(15):2035-8. PubMed ID: 18784466
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Production of the HIV-suppressive chemokines CCL3/MIP-1alpha and CCL22/MDC is associated with more effective antiretroviral therapy in HIV-infected children.
    Lambert JS, Machado ES, Watson DC, Sill AM, Lim JK, Charurat M, Cunha SM, Afonso AO, Oliviera RH, Tanuri A, DeVico AL.
    Pediatr Infect Dis J; 2007 Oct 01; 26(10):935-44. PubMed ID: 17901800
    [Abstract] [Full Text] [Related]

  • 9. Prolonged statin administration does not act on the cell-mediated immunity of HIV-infected dyslipidemic patients treated with a steady and effective highly active antiretroviral therapy. A two-year prospective study of statin versus fibrate administration.
    Manfredi R, Calza L, Chiodo F.
    J Biol Regul Homeost Agents; 2006 Oct 01; 20(1-2):1-9. PubMed ID: 18088548
    [Abstract] [Full Text] [Related]

  • 10. CD4 count and viral load time-courses in patients treated with highly active antiretroviral therapy and association with the CDC staging system.
    Collazos J, Knobel H, Casado JL, Grupo Español para el Estudio Multifactorial de la Adherencia (GEEMA).
    HIV Med; 2006 Nov 01; 7(8):504-13. PubMed ID: 17105509
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. CD4(+) cell count increase predicts clinical benefits in patients with advanced HIV disease and persistent viremia after 1 year of combination antiretroviral therapy.
    Loutfy MR, Walmsley SL, Mullin CM, Perez G, Neaton JD, Terry Beirn Community Programs for Clinical Research on AIDS, Canada HIV Trials Network.
    J Infect Dis; 2005 Oct 15; 192(8):1407-11. PubMed ID: 16170758
    [Abstract] [Full Text] [Related]

  • 13. Immunological responses during a virologically failing antiretroviral regimen are associated with in vivo synonymous mutation rates of HIV type-1 env.
    Mens H, Jørgensen LB, Kronborg G, Schønning K, Benfield T.
    Antivir Ther; 2009 Oct 15; 14(3):413-22. PubMed ID: 19474475
    [Abstract] [Full Text] [Related]

  • 14. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida.
    Enferm Infecc Microbiol Clin; 2009 Apr 15; 27(4):222-35. PubMed ID: 19246124
    [Abstract] [Full Text] [Related]

  • 15. Premature immunosenescence in HIV-infected patients on highly active antiretroviral therapy with low-level CD4 T cell repopulation.
    Molina-Pinelo S, Vallejo A, Díaz L, Soriano-Sarabia N, Ferrando-Martínez S, Resino S, Muñoz-Fernández MA, Leal M.
    J Antimicrob Chemother; 2009 Sep 15; 64(3):579-88. PubMed ID: 19608579
    [Abstract] [Full Text] [Related]

  • 16. Occult hepatitis B in persons infected with HIV is associated with low CD4 counts and resolves during antiretroviral therapy.
    Cohen Stuart JW, Velema M, Schuurman R, Boucher CA, Hoepelman AI.
    J Med Virol; 2009 Mar 15; 81(3):441-5. PubMed ID: 19152397
    [Abstract] [Full Text] [Related]

  • 17. Long-term statin use does not act on the temporal trend of CD4 cell count in patients on virologically effective HAART.
    Manfredi R, Calza L, Chiodo F.
    AIDS; 2006 Feb 14; 20(3):455-7. PubMed ID: 16439881
    [Abstract] [Full Text] [Related]

  • 18. Early initiation of highly active antiretroviral therapy fails to reverse immunovirological abnormalities in gut-associated lymphoid tissue induced by acute HIV infection.
    Tincati C, Biasin M, Bandera A, Violin M, Marchetti G, Piacentini L, Vago GL, Balotta C, Moroni M, Franzetti F, Clerici M, Gori A.
    Antivir Ther; 2009 Feb 14; 14(3):321-30. PubMed ID: 19474466
    [Abstract] [Full Text] [Related]

  • 19. HIV-infected patients with a large thymus maintain higher CD4 counts in a 5-year follow-up study of patients treated with highly active antiretroviral therapy.
    Kolte L, Ryder LP, Albrecht-Beste E, Jensen FK, Nielsen SD.
    Scand J Immunol; 2009 Dec 14; 70(6):608-13. PubMed ID: 19906203
    [Abstract] [Full Text] [Related]

  • 20. Immunogenetics of CD4 lymphocyte count recovery during antiretroviral therapy: An AIDS Clinical Trials Group study.
    Haas DW, Geraghty DE, Andersen J, Mar J, Motsinger AA, D'Aquila RT, Unutmaz D, Benson CA, Ritchie MD, Landay A, AIDS Clinical Trials Group.
    J Infect Dis; 2006 Oct 15; 194(8):1098-107. PubMed ID: 16991084
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.